Alzheimer's Drugs: Hype vs. Reality

0:00On April 16th, a new analysis from the Cochrane Group says so-called breakthrough Alzheimer's drugs don't deliver real benefits for patients. They target sticky beta amyloid plaques in the brain, slowing cognitive decline a bit, but the effect is way too small to change lives. These meds come with risks like brain swelling or bleeding, need infusions every two to four weeks, and cost a whopping 90,000 pounds, Fran, 18 month course privately, trials for drugs like Donanemaab and Leckinemaab marked the first time anything slowed brain damage in Alzheimer's after years of failures. Cochrane reviewed 17 studies with over 20,000 volunteers and found the amyloid clearing approach falls short overall. Doctors on the front lines, like Professor Edo Richard, tell patients these drugs probably won't help and burden families too much. Critics like Professor Robert Howard call out the hype for raising false hopes without solid science backing. But top scientists are pushing back hard, saying the review lumps old-failed drugs with

1:00newer ones that show modest gains. Experts like Professor Bart Dostruber argue it blurs the evidence and misses key differences in how the drugs work. Right now, the UK's NHS won't cover them, leaving private pay as the only option for most folks out of reach. Nice is taking another look, factoring in care of strain, while calls grow to chase other paths, like tackling brain inflammation.